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Abstract 
Fungi cause opportunistic, nosocomial, and community-acquired infections. Among fungal infections (mycoses) 
zygomycoses are exceptionally severe with mortality rate exceeding 50%. Immunocompromised hosts, transplant 
recipients, diabetic patients with uncontrolled keto-acidosis, high iron serum levels are at risk. Zygomycota are 
capable of infecting hosts immune to other filamentous fungi. The infection follows often a progressive pattern, 
with angioinvasion and metastases. Moreover, current antifungal therapy has often an unfavorable outcome.  
Zygomycota are resistant to some of the routinely used antifungals among them azoles (except posaconazole) and 
echinocandins. The typical treatment consists of surgical debridement of the infected tissues accompanied with 
amphotericin B administration. The latter has strong nephrotoxic side effects which make it not suitable for 
prophylaxis. Delayed administration of amphotericin and excision of mycelium containing tissues worsens 
survival prognoses. More than 30 species of Zygomycota are involved in human infections, among them Mucorales 
are the most abundant. Prognosis and treatment suggestions differ for each species what makes fast and reliable 
diagnosis essential. Serum sample PCR based identification often gives false negative results, culture based 
identification is time consuming and not always feasible. With the dawn of Zygomycota sequencing projects 
significant advancement is expected as in the case of treatment of Ascomycota infections.  
Keywords 
zygomycosis, mucormycosis, Mucorales, Zygomycota, nosocomial infection, fungal systematics, 
entomophtoromycosis, pathogenic fungi, mycosis, diabetes, transplant recipient, hematological malignancy, 
antifungal therapy, 
  
2 
 
Introduction 
Zygomycota is an artificial grouping of distantly related basal fungi. This term is broadly used for fungi belonging 
to Mucoromycotina, Entomophtoromucotina, Mortierellomycotina, Zoopagomycotina, and Kickxellomycotina. 
The common name zygomycosis stands for infections caused by organisms which diverged more than 800 MYA 
(Krings, Taylor, & Dotzler, 2013), preceding land colonization by plants. In consequence it should be broadly 
recognized that zygomycoses have a variable prognosis depending on the causal agent and patient’s condition. 
Mycology is undergoing a significant shift towards molecular based taxonomy aiming at a more consistent 
classification and nomenclature. A robust classification reflecting biological similarities is of great significance 
for medical purposes. The biochemical and physiological variability among fungal taxa lead to measurable effects 
among them antifungal resistance (Nikolaos G Almyroudis, Sutton, Fothergill, Rinaldi, & Kusne, 2007; Farina, 
Marchesi, Passera, Diliberto, & Russello, 2012). Fast and accurate species (or at least genus) recognition is 
essential for a successful treatment in the case of less common fungi. Yet, in most laboratories such in depth 
classification is not routinely performed, because these genera cannot be easily differentiated for example 
histopathologically. 
The broadly used and recognized term Zygomycota should be abandoned in the future in favor of proper taxonomic 
names. Since the clinical manifestations and development of the infections with Mucorales and Entomophthorales 
are significantly different the name “zygomycosis” should also be abandoned in favour of entomophthoramycosis 
(entomophtoromycosis), mortierellomycosis and mucoralomycosis (mucormycosis). However here, when 
describing common features of many taxa, we will apply the term Zygomycota. Emerging Zygomycota infections 
are becoming a serious threat at transplantation and other wards with immunocompromised patients. This 
phenomenon become more pronounced after the introduction of serum-based detection, diagnostic imaging and 
modern antifungals (voriconazole) which enabled efficient treatment of aspergillosis (Pongas, Lewis, Samonis, & 
Kontoyiannis, 2009). Mucorales are the third most common agent of systemic mycoses after invasive aspergillosis 
and candidiasis in hematology patients (Kontoyiannis et al., 2010). This constantly growing group of susceptible 
patients together with improvements in the management of invasive aspergillosis and candidiasis result in 
increased interest in zygomycoses. In contrast to aspergillosis most cases of zygomycosis are fatal despite the 
administration of antifungal therapy (Lewis et al., 2012; Pagano et al., 2006; Roden et al., 2005). The number of 
risk patients is constantly growing with the ubiquity of diabetes and immunosuppressive treatment. Furthermore 
Zygomycota are able to colonize hosts not susceptible to other opportunistic fungal infections among them diabetic 
patients and intravenous drug users (Roden et al., 2005). Especially representatives of the genus Basidiobolus 
(Vikram HR, Smilack JD, Leighton JA, Crowell MD, 2012) and of the family Saksaneaceae (Baradkar, Mathur, 
Taklikar, Rathi, & Kumar, 2008; Thomas, Shah, Mathews, & Chacko, 2008) have been reported to infect healthy 
hosts.  
Here, we revise current knowledge on nomenclature, pathogenesis and diagnostics of zygomycosis (mainly 
mucormycosis). 
Biology 
Mucoromycotina representatives are ubiquitous organisms present all over the world in the soil, infecting plants 
and other fungi (Hoffmann et al., 2013). Importantly, the same species are found in clinical samples and used in 
food fermentation. Entomophtoromycotina groups more than 250 entomopathogenic, soil and litter associated 
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species (Gryganskyi et al., 2013). Mortierellomycotina (Wagner et al., 2013) harbor more than 100 taxa of 
saprotrophic soil organisms. 
The knowledge on pathogenic Zygomycota ecology is very limited and often anecdotal. Understanding the 
lifestyle of pathogenic species is essential to understand the epidemiology and to formulate recommendations for 
risk patients. In medical mycology species from order Mucorales are the most common Zygomycota 
representatives. 
Mucorales reproduce both sexualy, by zygospores formed after the fusion of hyphae of different mating types, and 
asexualy through sporangiospores produced within sporangia. However, in most species zygospores production is 
more rare and the conditions necessary for their formation and germination remain unknown. In turn, asexual 
spores are produced massively and they can differ in character (Ainsworth, 2008). Mucorales produce not only 
dry sporangiospores dispersed by the air but also wet sporangiospores, less prone to aerosolization. Spore size and 
hydrophilic/hydrophobic character impacts the dispersal of fungi. Human infecting Zygomycetes are relatively 
hydrophilic what limits the everyday exposition to their spores even if they are ubiquitous in spoiled food and 
pathogenic strains do not differ from environmental samples (Lu et al., 2013). 
Even the most ubiquitous among Zygomycota (Rhizopus and Mucor) are less common in air samples than benign, 
plant-associated Alternaria and Cladosporium (Segvić Klarić & Pepeljnjak, 2006)(Vesper et al., 2005) involved 
in human allergies. The prevalence of Mucorales spores in dust and spoiled food compared to air samples is 
consistent with the onset of infections after earthquakes and massive inhalation of spores. Human pathogenic 
Ascomycota are broadly encountered in air samples whereas Zygomycota are less abundant in air samples (Ejdys, 
2007; Gniadek & Macura, 2007; I. El-Herte, 2012). In liquid culture Mucor circinelloides produces yeast cells, 
however the role of yeast-forms in infection is unknown (Khan, Ahmad, Brazda, & Chandy, 2009). Furthermore 
M. circinelloides produces sporangiospores of different sizes depending on the mating type variant (Desjardins et 
al., 2011). The bigger sporangiospores are able to lyse macrophages what makes them more virulent to a 
mammalian host. 
Until recently it was not clear whether the dimorphic switch between aerobic hyphal growth and multi-budded 
yeast growth under anaerobic/high CO2 conditions is related to virulence in Mucorales. Lee and colleagues (Lee, 
Li, Calo, & Heitman, 2013) showed that a calcineurin inhibitor tacrolimus (FK506) prevents hyphal growth of 
Mucor spp. Furthermore, the cAMP dependent protein kinase A (PKA) is involved in the dimorphic transition 
alike in other dimorphic fungi (Candida species, Cryptococcus neoformans, Cryptococcus gattii and Aspergillus 
fumigatus). The yeast-locked mutants were less virulent than wild type strains suggesting that hyphae are more 
virulent or the dimorphic switch is important for the pathogenicity of this fungus. Finally, the authors showed that 
calcineurin participates in hyphal polarity development and spore size dimorphism. Calcineurin is a promising 
drug target against many fungal pathogens with dimorphic growth. 
Table 1. A summary of differentiating features between filamentous fungi.  
Character Ascomycota (eg. Aspergillus)  Zygomycota (eg. Mucor) 
Spores hydrophobic spores (conidia), 
ascospores 
dry and wet sporangiospores, zygospores 
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Hyphae narrow (2-3μm), septate, branching in 
different angles 
broad (6-16μm), coenocytic, orthogonal 
ramifications 
Cell wall composition more glucan  
galactomannan present 
more chitin  
galactomannan absent 
Mucoralean hyphae are often heavy and have a bigger diameter than in Ascomycota. Hyphae diameter and size 
determine the efficacy of phagocytosis by macrophages. They differ in cell wall composition as well, they have 
less glucan and more chitin compared to Ascomycota. This change in biochemistry determines antifungal 
susceptibility/resistance, because most antifungal drugs target either the cell wall machinery or components. They 
are galactomannan negative thus serum tests based on this feature can differentiate among Ascomycota and 
Zygomycota, but only confirming the presence of Ascomycota and providing no information about 
presence/absence of Zygomycota. Zygomycota are resistant to most of the newer antifungals: voriconazole and 
echinocandins, which are very efficient against Candida and Aspergillus mycoses. The three orders of Zygomycota 
infecting humans have different susceptibility/resistance patterns. 
In vitro studies revealed the potential for biofilm formation for R. oryzae, L. corymbifera and R. pusillus but not 
for A. elegans (Singh, Shivaprakash, & Chakrabarti, 2011). The biofilm matrix is formed with glucosamine as the 
dominant dry component. 
Table 2. Summary of differentiating features of entomophtoromycosis and mucormycosis  
feature mucoromycosis entomophtoromycosis 
progression of the infection rapidly invasive local 
immune reaction acute chronic 
host immunity compromised competent 
localization systemic cutaneous, soft tissue 
lipase - + 
keratin degradation - + 
thermotolerance  + - 
Rhizopus oryzae is claimed to possess extraordinary genome plasticity due to a whole genome duplication which 
resulted in an elevated number of genes including those involved in host-pathogen interactions (Lewis et al., 2012; 
Ma et al., 2009). Currently more Zygomycota genomes have been sequenced including Lichtheimia hyalospora, 
Mucor circinelloides, Mortierella elongata, Rhizopus microsporus and Conidiobolus coronatus what will enable 
comparative studies and accelerated screening of drug targets. Comparative analyses will facilitate the 
identification of conserved components of the fungal cell machinery. Based on the sole gene count and genome 
size comparisons it is clear that Rhizopus oryzae is an exception regarding the number of genes in the whole 
collection of currently sequenced Zygomycetes with the average gene number of 11 thousand genes. Table 3 lists 
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estimated genome sizes and predicted gene numbers for Zygomycetes present in the JGI sequencing center 
database. 
Table 3. Currently sequenced Zygomycota genomes stored by JGI 
Organism and project name genome size number of genes 
Coemansia reversa NRRL 1564 v1.0 21,838,014 7,347 
Umbelopsis ramanniana AG # v1.0 23,077,072 9,931 
Conidiobolus coronatus NRRL28638 v1.0 39,903,661 10,635 
Rhizopus microsporus var. microsporus v1.0 25,972,395 10,905 
Mucor circinelloides CBS277.49 v2.0 36,587,022 11,719 
Lichtheimia hyalospora v1.0 33,282,407 12,062 
Gonapodya prolifera v1.0 48,794,828 13,902 
Mortierella elongata v1.0 49,959,475 14,964 
Phycomyces blakesleeanus NRRL1555 v2.0 53,939,167 16,528 
Rhizopus oryzae 99-880 from Broad 46,087,117 17,467 
Systematics 
Fungal systematics have been recently reorganized (Hibbett & Taylor, 2013) what resulted in a temporary chaos 
in the nomenclature. A revised taxonomic classification has been introduced for several of the human and animal 
fungal pathogens also from the previous Zygomycota phylum (Gryganskyi et al., 2013; Hoffmann et al., 2013; 
Wagner et al., 2013). These changes in nomenclature should better reflect biological differences among taxa. A 
reliable source of valid nomenclature are: Index Fungorum and MycoBank. Zygomycota themselves are currently 
not a valid taxon, instead more subphyla and orders are proposed. 
Only three of 13 orders of known Zygomycetes, namely the Mucorales, the Mortierellales and the 
Entomophtorales, harbour animal and human pathogens (Voigt, Vaas, Stielow, & de Hoog, 2013). However 
Mortierella wolfii is a cattle pathogen, the documentation of human infections is scarce and no cases were 
described since 2000. In consequence, we will focus only on Mucorales and Entomophtorales infections, called 
mucormycosis and entomophthoromycosis respectively). Supplementary Table S1 lists Mucoromycotina, 
Mortierellomycotina and Entomophoromycotina involved in human infections with synonymic names and 
examples of case reports. Mucoromycotina group most of the human pathogenic Zygomycota.  
Some taxa have been recently revised, deemed species complex and in consequence divided into more taxa. 
Among them Apophysomyces sp. accounts now for four taxa with differences at spore shape and ITS sequence 
levels (E Alvarez et al., 2010). Due to the introduction of separated taxa in 2010 most literature refers to A. elegans. 
However, future work should refer to the newest nomenclature. A similar pattern involves Saksenaea vasiformis, 
which is now considered a species complex and in consequence was split into more taxa characterized by spore 
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shapes (E Alvarez et al., 2010). Among the most characteristic pathogenic Mucorales Rhizomucor variabilis was 
moved to the Mucor genus based on molecular characteristic and renamed Mucor irregularis (Eduardo Alvarez et 
al., 2011). Other taxa suspected to be species complex were confirmed as true species. Rhizopus microsporus was 
revised as a single species and its varieties might be just environmental variants. Importantly, foodborne, 
environmental and clinical strains are indistinguishable (Dolatabadi, Walther, Gerrits van den Ende, & Hoog, 
2013). This observation supports the opportunistic character of mucormycoses  
Host - fungus interaction 
Key factors involved in fungal infections seem to be shared among distantly related fungi pathogenic against 
different hosts (Gauthier & Keller, 2013; Lee et al., 2013). 
Respiratory tract is the main entrance for fungi, among them for Zygomycetes. Inhaled aerosolized spores are 
removed by the ciliated epithelium cells moves. If some manage to overcome this barrier the alveolar macrophages 
phagocyte and destroy most spores. Healthy gastrointestinal tract and skin are good barriers to Zygomycetes. It is 
not surprising that most of skin infections are a consequence of direct inoculation due to severe trauma. 
Gastrointestinal infections are most common in neonates, which had not developed proper immune mechanisms. 
The description of host pathogen interactions at a molecular level shows differences in the mechanisms of 
aspergillosis and mucoromycosis including host immune response and susceptibility to macrophage induced 
hyphal damage (Roilides, Kontoyiannis, & Walsh, 2012). Furthermore biological features of the causing agent 
determine the location and progress of the infection, leading to a more localized infection in entomophtoromycosis 
and a progressive and potentially disseminated infection in mucormycosis. Entomophtorales specialized in cutin 
degradation exert keratinolytic enzymes, in consequence entomophtoromycoses are usually superficial and 
gastrointestinal infections. In contrast with Entomophtorales human infecting Mucorales are usually thermo 
tolerant what makes them able to invade internal body parts and form a chronic infection. 
The interplay between pathogens and hosts varies among fungal agents and host condition. However, some general 
trends can be drawn. Most of the mechanisms are known from animal data, the latter should be considered with 
caution as the inflammatory reaction is different in rodents and apes. The role of immune system in preventing 
and eliminating fungal infections involves an inflammatory reaction. Inflammation triggered by Zygomycota is 
usually less visible than in aspergillosis. Ascomycota are recognized by both TRL2 and TRL4 receptors whereas 
Zygomycota are recognized solely by TLR2 receptors (Roilides et al., 2012). There is another major difference 
compared to aspergillosis regarding the involvement of T lymphocytes. This is because, innate immunity is 
indispensable to fight a Zygomycota infection and the acquired immunity involvement is not that pronounced. 
Hovewer, Mucorales specific T cells and NK cells can be found both in patients and in healthy individuals. These 
findings pave the way for potential diagnostic tests and adoptive immunotherapy (Ibrahim & Kontoyiannis, 2013). 
One of the most characteristic features of zygomycoses is their occurrence in diabetic patients. Some aspects of 
the interplay between the fungus and diabetic patients has been revealed at a molecular level. During the infection 
R. oryzae binds to GRP78 receptors (Ibrahim, Spellberg, Walsh, & Kontoyiannis, 2012; Liu et al., 2010). The 
expression of GRP78 receptor coding genes is affected by acidosis, iron and glucose levels which are observed in 
diabetic patients (high blood sugar levels and available iron). In such a scenario R. oryzae become more resistant 
to neutrophils, which are susceptible to low pH conditions. One taxon may produce hyphae and spores of variable 
size. Phagocyte-induced damage is related to target mass, bigger hyphae are harder to phagocyte. Schmidt and 
colleagues (Schmidt et al., 2013) demonstrated that both unstimulated and IL-2 prestimulated human NK cells 
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damage Rhizopus oryzae hyphae, but do not affect resting conidia. They concluded that the damage of the fungus 
is mediated, at least in part, by perforin. R. oryzae hyphae decrease the secretion of immunoregulatory molecules 
by NK cells, such as IFN-γ and RANTES (Regulated on Activation, Normal T-cell Expressed and Secreted), 
indicating an immunosuppressive effect of the fungus.  
A study on the activity of human polymorphonuclear leukocytes (PMNLs) against R. oryzae, R. microsporus and 
L. corymbifera revealed that interferon (IFN)- gamma and granulocyte-macrophage colony-stimulating factor 
(GM-CSF) augment the hyphal damage of all 3 zygomycetes. Additionally, this effect was more pronounced 
against L. corimbifera than against both Rhizopus species (Gil-Lamaignere et al., 2005). 
Genus specific patterns could be drawn from pulled data from multiple infections. It is currently known that 
Cunninghammella is more aggressive than Lichtheimia in diabetes patients (Roilides et al., 2012). It induces low 
TNFa levels and is resistant to hyphae damage by macrophages. In rare cases can invade an immunocompetent 
host (Gupta et al., 2011). What suggests some specific properties of Cunninghammella compared to other 
Mucorales. Cunninghammella infections have higher mortality rates than other more common infections (Roden 
et al., 2005). 
Epidemiology 
Risk factors 
There are several risk factors associated with opportunistic fungal infections among them zygomycoses. Diabetic 
ketoacidosis (B Rammaert, Lanternier, Poirée, Kania, & Lortholary, 2012; Roden et al., 2005), treatment with 
corticosteroids (Prabhu & Patel, 2004; Zaki, Elkholy, Elkady, & Abdel-Ghany, 2013), deferoxamine in patients 
on dialysis (Chayakulkeeree, Ghannoum, & Perfect, 2006) and immunosuppressive drugs (Ibrahim et al., 2012) 
enhance susceptibility to develop zygomycosis. Neutropenia (Ibrahim et al., 2012; Anna Skiada et al., 2013), 
malnutrition (Sun & Singh, 2011), cytomegalovirus infection (Mysorekar & Rao, n.d.) and extended wounds/burns 
(Andresen et al., 2005; Ledgard, van Hal, & Greenwood, 2008)) are also predisposing conditions associated with 
zygomycosis. 
According to the main reviews by Roilides (Roilides et al., 2012) and Ibrahim (Ibrahim et al., 2012) neutropenia, 
diabetes with blood hyperglycemia and low pH, Fe overload, corticosteroid therapy and direct inoculation in result 
of trauma are the main risk factors. Neutropenic patients are at increased risk, whereas patients with AIDS are not. 
This is because, T lymphocytes are not key players in fighting against Zygomycota infection. The phagocytes 
provide antifungal activity via oxidative metabolites and defensins (Ibrahim et al., 2012). Immunosuppression 
leading to neutropenia encountered in transplant recipients renders them susceptible to zygomycosis. 
Corticosteroid therapy also influences neutrophiles and their activity against fungi. 
It has been found that (Roden et al., 2005) diabetic patients are exceptionally susceptible to sinusitis infections. 
Diabetic patients have an altered innate immunity with reduced PMNLs chemotaxis, impaired transmission 
through vascular endothelium and reduced superoxide production (Peleg, Weerarathna, McCarthy, & Davis, 2007; 
B Rammaert et al., 2012). 
Fe overload - iron is indispensable for vital life processes as a such is a limiting factor. Pathogens developed many 
traits to acquire iron from the host. Zygomycetes are not an exception, here. Deferoxamine therapy is suspected to 
facilitate Zygomycota infection by making iron available. 
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Healthy skin provides an efficient barrier against Mucorales, thus skin trauma provides a risk for developing 
mucormycosis (Ibrahim et al., 2012). This condition is favorable for fast growing opportunistic organisms. Contact 
with soil, food, water containing fungi can be detrimental for either burned or severely wounded patients. 
Table 4. Infection prevalence and its main features (George Petrikkos et al., 2012; Blandine Rammaert et al., 
2012; Roden et al., 2005; Spellberg, Edwards, & Ibrahim, 2005).  
Underlying 
disease/condition 
Percent of patients with 
zygomycosis 
The most common form 
of infection 
Mechanism and 
predisposing factors 
Hematological 
malignancy 
11-17  pulmonary; dissaminated neutropenia, voriconazole 
prophylaxis 
HSCT recipients 1,2-5 rhinocerebral; pulmonary steroid prophylaxis for 
GvsH diseas, neutropenia, 
voriconazole prophylaxis 
Diabetes mellitus 17 - 36(74) rhinocerebral, sinus acidosis - increasing iron 
level 
acidosis and 
hyperglycemia - 
negatively impact 
neutrophil chemotaxins 
and phaocytic activity 
Solid organ 
transplantation 
(0.6)7 - 13 
23 
pulmonary, liver and other 
transplant organ 
transplant contamination 
Deferoxamine therapy 1-6 dissaminated, pulmonary increasing iron level 
Burns, trauma in accident 13 - 20 cutaneous, even 40% of 
infections get 
disseminated 
disruption of skin barrier 
(spore inoculation) 
Malnourished patients 3 gastrointestinal digestion of the fungi, 
(Premature) neonates 3-21 gastrointestinal  
Sources and routes of infection 
Mucorales are ubiquitous in environment. They may be present in rotten organic debris (foods, fruits, vegetables, 
seeds and nuts, plants). Sporangiospores are easily aerosolized and dispersed in air what is may be the source of 
infection by inhalation of spores. However, occurrence of sporangiospores in indoor and outdoor air is less than 
conidia of aspergilli and other molds. 
There are three mainly route of infection of Zygomycota. The most common is via respiratory system - sinuses 
and lungs. The wards where are patients with neutropenia and other risk factor of invasive fungal infection should 
monitor air-conditioning, and there are not allowed plants as potential sources of fungal growth and sporulation. 
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Published data describing the levels of zygomycete sporangiospores in outdoor and indoor air in relation to 
seasonal variation is scarce. It was suggested on the base of two articles from Near East and analyses of seasonal 
presence of sporangiospores in outdoor air that mucormycosis may occur seasonal in the end of summer and 
autumn when the month are warm and humid (I. El-Herte, 2012). 
The second route of infection is via directly inoculation of fungal propagules into human body. It can be iatrogenic 
or common acquired. Nosocomial infection can be due to contaminated medical devices: ostomy pouching system, 
adhesive bandage, wooden tongue depressors, subcutaneous insulin infusion pump, peritoneal dialysis, 
intravascular devices or contamination during medical procedures: dental extraction and local anesthesia, 
intramuscular injection of corticosteroids, vitamins and anticoagulant, nasal packing, contamination of grafts and 
during transplantation. Common acquired inoculation of zygomycota fungi may occur as a result of traffic 
accident, burns when the contaminated soil, water, plant debris or other things has a contact with injured skin and 
tissues. Infection can also occur by the insect bites. This route of infections are dominant in healthy patients. The 
less common of Zygomycota infection is oral route (Blandine Rammaert et al., 2012). 
Among nosocomial sources of infection there are reported cases of contaminated biomedical devices and building 
constructions. In a review of 169 cases by Rammaert and colleagues (B Rammaert & Lanternier, 2012) list a 
variety of sources of infections among them: grafts, ostomy bags, adhesive bandages, water, wooden tongue 
depressors, dental extraction and local anesthesia, blood glucose self-monitoring equipment, subcutaneous insulin 
infusion pump, peritoneal dialysis, intravascular devices, intramuscular injection of corticosteroids and vitamins, 
nasal packing. Neonatalogical, hematological, transplantation and burn units should monitor their conditions to 
ensure patients well-being. 
Special focus should be directed on donor-derived filamentous fungal infections in transplant recipients (Bakr et 
al., 2008) which have a fatal outcome (Blandine Rammaert et al., 2012). Environmental sources of infection are 
dominant in healthy patients with challenged skin barrier - after trauma (car accident, burn) among them soil 
/decaying organic matter (Austin, Finley, Mikkelson, & Tibbs, 2013) and water (Ribeiro et al., 2010) should be 
considered. Even plant pots in hospitals can be a source of infection for immunosuppressed patients. 
Prevalence 
In the general population zygomycosis is a very rare disease. Orphanet (the Orpha number i.e. the Orphanet 
identifier for zygomycosis is 73263) classified it as a rare infectious disease however its prevalence is not known. 
There are several estimations of zygomycosis/mucormycosis incidence, showing some discrepancies. A more 
accurate assessment of zygomycosis prevalence is currently not feasible due to incomplete identification and 
documentation. However, some best practice approaches have been introduced like the Working Group on 
Zygomycetes by the International Society for Human and Animal Mycology (ISHAM). Rees and colleagues (Rees, 
Pinner, Hajjeh, Brandt, & Reingold, 1998) estimated the incidence of mucormycosis to be 1.7 cases per million 
people per year analyzing a population-based study in USA performed in the 90’s. A Spanish multicenter, 
population-based study, based on 6 diagnosed cases of zygomycosis in Spain in 2005 (Torres-Narbona et al., 
2007), showed that the incidence of zygomycosis was 0.43/1,000,000 inhabitants per year and 0.62/100,000 
hospital admissions. That gives 430-1700 cases per million per year worldwide. However, Brown (Brown et al., 
2012) estimated that more than 10000 life-threating cases of mucormycosis occur worldwide per year with 30-
90% mortality rate within infected persons. 
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Postmortem prevalence evaluation shows that mucormycosis is 10–50-fold less frequent than both candidiasis and 
aspergillosis with a frequency of 1–5 cases per 10 000 autopsies (Hotchi, Okada, & Nasu, 1980; Tietz, Brehmer, 
Jänisch, & Martin, 1998; Yanagisawa, Friedman, Kundargi, & Smith, 1977). Zygomycosis represents 8.3%–13% 
of all fungal infections encountered at autopsy in high-risk patients (G Petrikkos & Skiada, 2012). 
Males are more likely affected by zygomycosis than women (58-68% of cases - (A Skiada et al., 2011)(Rüping et 
al., 2010)(Lanternier et al., 2012)(Roden et al., 2005)). This fact can be explained by hematological malignancies 
(HM) (and most cancers) incidence being generally lower in women than men. The smaller number of cancers in 
women is a well-documented phenomenon and could be in part the result of a lower exposure to environmental 
and occupational risk factors in women than men (Cook et al., 2009; Sant et al., 2010). Nwannadi (Omoti, 
Nwannadi, Obieche, & Olu-Eddo, 2012) reports that HM more often affects male (56%) and adult (>15yo) 83% 
patients. However, Skiada found that there is no predilection for sex in cutaneus zygomycosis which affected 
generally healthy persons (A Skiada, Rigopoulos, & Larios, 2012). 
In 2011, a large prospective multinational European study based on 230 patients with zygomycosis showed that 
the most common predisposing conditions were hematological malignancies (44 %), trauma (17 %), DM (17 %), 
and hematopoietic SCT (9 %) (A Skiada et al., 2011). 
Haematological malignancies 
Patients with hematological malignancies (HM) either with or without hematopoietic stem cell transplantation 
(HSCT) constitute the most commonly infected group. They account for up to 44% percent of all cases of 
zygomycosis (George Petrikkos et al., 2012; Anna Skiada et al., 2013). 
The retrospective cohort study was conducted in hematology wards of either tertiary care centers or university 
hospitals located throughout Italy, between 1999-2003. Five hundred and thirty-eight proven or probable IFI 
(invasive fungal infections) on 11802 patients with newly diagnosed hematology malignancies (AML, ALL, CML, 
CLL, NHL, HD and MM) were documented. The overall incidence of IFI was 4.6%. Zygomycetes in this study 
occurs in 1,2/1000 (0,12%) HM patients (most frequent among AML and ALL patients - 0,3% patients) with 
64,3% mortality rate (attributable mortality rate 0,08%). In this study zygomycetes were fourth agents of IFI 
following (1) Aspergillus, (2) Candida and (3) Fusarium) (Pagano et al., 2006). 
In another study conducted in Southern Italy during 18-months, among 589 (475 adults and 114 pediatrics) patients 
with newly diagnosed HM (AML, NHL, ALL, CLL, MM) twenty-seven episodes of IFIs were documented 
(Montagna et al., 2012). The overall incidence was 4.6%. Of the 27 documented IFIs, 16 were caused by yeasts 
(13 in adult patients and 3 in pediatric patients) and 11 by filamentous fungi (all in adult patients). A total of eleven 
mold infections (40.7%, 10 aspergillosis and 1 zygomycoses) were reported only in adult patients (incidence 
2.3%). Occurrence of zygomycosis was slightly higher than observed in Pagano study (Pagano et al., 2006)- 
1,6/1000 vs 1,2/1000 HM patients. 
Neofytos and colleagues (Neofytos et al., 2009) performed a multicenter, prospective, observational study to assess 
the epidemiological characters and outcomes of invasive fungal infection (IFI) in hematopoetic stem cell transplant 
(HSCT) recipients in North America. In this study were included 234 adult HSCT recipients with total 250 cases 
of IFI. The most frequent was invasive aspergillosis (59,2%) followed by invasive candidiasis (24,8%) and 
zygomycosis (7,2%), and other molds (6,8%) (Alsharif et al., 2009). In 178 autopsies of HSCT recipients (45,1%) 
infectious etiologies were found to contribute to the cause of death. Fungal infection were found in 93 cases 
11 
 
(23,5%). Among fungal infection by cultivable species the most common was Aspergillus sp. (44,6%) followed 
Candida (33,9%) and Zygomycota (7,1%) and Pneumocystis (7,1%). 
This data suggest that zygomycetes infection occurs in 1,7% patients with HSCT recipients (17 cases of 
zygomycosis per 1000 HSCT recipients) 
Diabetes 
The another risk factor is diabetes mellitus. Zygomycosis occur mainly in patients with uncontrolled diabetes 
especially with ketoacidosis. In 2012 WHO estimated the number of diabetic patients to 220 mlns (current 
estimates from WHO Fact sheet N°312, Updated March 2013: 347 million people worldwide have diabetes 
(Danaei et al., 2011)). Zygomycoses are associated with DM in 17-36% of cases. If we take into account estimates 
that worldwide are 10000 patients with zygomycosis that gives us 0,9-1,8 zygomycosis per 100 000 diabetic 
patients (approximately 0,0009-0,0018%). 
The problem of zygomycosis in diabetic patients is associated with poverty and malnutrition for example in India 
where uncontrolled DM was the most commonly found predisposing factor in 74% (n = 131) of the 178 cases of 
zygomycosis identified between 2000 and 2004 (Arunaloke Chakrabarti et al., 2006). In contrast to France where 
DM was associated only with 9% of 531 cases of zygomycosis reported between 1997 and 2006 (Lanternier et al., 
2012). 
Solid organ transplantation 
Zygomycoses have been reported from different organ such as. renal, liver, heart and lung transplantations. 
Zygomycosis was generally considered to be a rare complication in solid organ transplant recipients (N G 
Almyroudis et al., 2006) Incidences of zygomycosis in solid organ transplant recipients are estimated from 0,4 to 
16% depending on the procedure and geographical area (Lanternier et al., 2012). The most recent multicenter 
prospective study conducted in USA found that among 16457 transplant patients 12 had Mucorales infection 
(0,07%), among particular organ recipients Mucorales infection occurred as follow: lung 2/1179 - 0,17%, liver 
7/4361 – 0,16%, kidney 3/8494 - 0,03%; pancreas (1174) , heart (1159), small bowel (69) there were no 
zygomycosis infection (Kontoyiannis et al., 2010). 
Although zygomycoses are relatively rare they are characterized by a severe course and high mortality rate. Early 
diagnosis of the infection is still a challenge and the demand for better diagnosis is growing with the increasing 
number of reported cases. The latter is possibly caused by a species shift resulting from the common prophylaxis 
of fungal infection with azoles (fluconazole and voriconazole) at risk wards. Zygomycota are not susceptible to 
azoles except for posaconazole. 
Clinical manifestations 
There are five main clinical manifestations of Zygomycosis (G Petrikkos & Skiada, 2012) rhinocerebral, 
pulmonary, gastrointestinal, cutaneous and disseminated. Spellberg and colleagues listed sixth group of 
miscellaneous mucormycosis presentation in which, they included brain involvement without sinus infection, 
endocarditis, pyelonephrititis, bones infection, external otitis etc (Spellberg, Edwards, et al., 2005). 
Among patients from group of risk of zygomycosis the most common manifestation is rhino-(orbital)-cerebral (33-
49%), followed by cutaneous (10-16%, pulmonary (10-11%), disseminated (6-12%) and gastrointestinal (2-11%). 
In immunocompetent/otherwise healthy patients the most representative clinical form was: 
cutaneous/subcutaneous form (42.5% of patients), followed by the rhino-orbito-cerebral (38%) and genitourinary 
(8.5%), disseminated and pulmonary infections (Mignogna, Fortuna, & Leuci, 2011). 
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Rhinocerebral mucormycosis 
The rhinocerebral mucormycosis is the most common form present in both neutropenic hematologic and diabetic 
patients. Initial symptoms are nonspecific involving headaches, altered mental status, fever, and eye syndromes 
lacrimation, irritation, or periorbital anesthesia. Unilateral vision disturbance and further changes involving ptosis, 
proptosis or loss of extraocular muscle function are signs of the progressing infection towards the retro-orbital 
region or the central nervous system (CNS). Necrotic black lesions on the hard palate, necrotic turbinates, septum 
perforation should be carefully inspected. The radiographic image of the infection can be mimicked by bacterial 
and other fungal infections as well as tumors. Scheckenbach and colleagues (Scheckenbach et al., 2010) reported 
that initial CT scanning was not informative and most manifestations were not specific, only histopathology 
provided sufficient data to establish a reliable diagnosis. A proper management of the primary disease is essential 
for a favorable outcome. 
Pulmonary mucormycosis 
Pulmonary mucormycosis usually occurs in patients with profound neutropenia, hematologic malignancies, on 
corticosteroid therapy or diabetes. The symptoms are not specific and involve fever, chest pain and cough. 
Neutropenia and coagulation dysfunctions make tissue collection inadvisable in some cases. Radiographic or CT 
scans showing multiple (>10) nodules or pleural effusions can be a sign of fungal infection. Although other 
mycoses, bacterial infections or malignant invasions should be considered. 
Gastrointestinal mucormycosis 
Gastrointestinal mucormycosis is a very rare form of infection. It is associated with severe malnutrition and 
premature birth. The infection is thought to be a consequence of the ingestion of fungi. The symptoms including 
fever, pain, vomiting, diarrhea, and constipation are non-specific. The infection might lead to ischemic infarction 
and ulceration. Stomach, terminal ileum, and colon are the most common sites, however any part of the 
gastrointestinal tract can be colonized. The diagnosis requires direct examination and biopsy, and is often only 
performed at autopsy. 
Cutaneous (skin) mucormycosis or entomophtoromycosis 
Cutaneous infection can be either primary or secondary. A primary infection is developed in patients who suffered 
burn or other trauma. The infection is caused by direct inoculation during an accident or nosocomial. The disease 
manifestation involves erythema, pus, abscess formation, tissue swelling, necrosis and pain of the infected area. 
The skin appears red and indurated and the necrosis can be observed as black eschars. The tissue necrosis can 
progress to gangrenous cellulitis. 
Cutaneous infection can be a secondary locus in patients with disseminated infection from respiratory tract. 
Cutaneous mucormycosis has been reported in diabetic patients. 
Disseminated mucormycosis 
This form of mucormycosis is the hardest to control and constitutes the greatest threat to the patient. When two or 
more non-contiguous organs are involved an infection can be considered disseminated. These often include lung 
and CNS colonization, with lung infection being often the primary infection site. The involvement of lung and 
skin is a sign of higher risk of CNS invasion as well. Since the disseminated form often involves CNS colonization 
the disease can by manifested by changes in the mental status. Other internal organs can be secondarily invaded 
during colonization among others the spleen, liver and even heart leading to pain of the infected organ.  
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Pediatric cases 
Zaoutis and colleagues consider that pediatric cases should be treated as a separate category (Prasad, Vaughan, & 
Zaoutis, 2012; Roilides, Zaoutis, Katragkou, Benjamin, & Walsh, 2009). There is limited information about 
zygomycoses in children. Infection in children is different: they tolerate more intensive treatment and GI tract 
infections are fatal, being the third most common of zycomycoses manifestations in neonates. 
Diagnosis of Zygomycota infections 
Zygomycosis is still a challenge for diagnostics especially considering that the early diagnosis is the best drug in 
zygomycoses. The diagnosis relies on clinical findings, risk factor analysis, histopathology and culture samples 
inspection. The clinical signs vary with the form and stage of the infection. In the rhinocerebral zygmycosis classic 
clinical features include facial swelling, with ocular involvement. Patients often report facial and eye pain, 
proptosis and visual disturbances that are signs of the involvement orbital structures (muscles, nerves and vessels).  
Black necrotic lesions can also occur for example on the hard palate. Pulmonary zygomycosis manifests itself with 
nonspecific symptoms such as fever, cough and dyspnea; when fungi invade vessels also hemoptysis may occur. 
Radiographic findings can be vague and often overlap with other mold infections. The presentation of pulmonary 
zygomycosis often resembles that of an invasive aspergillosis in severely immunocompromised patients for 
example HSCT recipients. Comparison of the CT imaging features of pulmonary zygomycosis and invasive 
pulmonary aspergillosis has shown that the presence of multiple nodules (>10)  and, to a lesser degree, the presence 
of pleural effusions, favored the presence of  the former diseases. Additionally, micronodules seen on the initial 
CT scans were more commonly observed in patients with pumonary zygomycosis (Chamilos, Marom, Lewis, 
Lionakis, & Kontoyiannis, 2005). Gastrointestinal zygomycosis may occur in patients with severe malnutrition. 
Clinical picture mimics intra-abdominal abscess. Unfortunately the diagnosis is often made at autopsy. 
Differentiation with other fungal infection is very important because Zygomycota are resistant to voriconazole, a 
drug successfully used in the treatment of invasive aspergillosis.  
The diagnosis can be performed on several levels i) identification of an invasive mold infection ii) distinguishing 
between Ascomycota and Zygomycota iii) species/genus identification. 
Diagnostic imaging 
Diagnostic imaging are useful in early diagnosis of rhinocerebral, non-enhanced paranasal sinuses or lungs lesions. 
This methods allows to preliminary recognition of probably Mucorales infection. Computer tomography (CT) have 
a higher sensitivity and allows to earlier diagnosis than classical radiograph techniques. CT scans can reveal lesions 
caused by angioinvasive fungi not visible in conventional radiographs and prior to other clinical manifestations 
(Walsh, Gamaletsou, McGinnis, Hayden, & Kontoyiannis, 2012). CT gives opportunity to shows mucosal 
thickening and early bone destruction. Lesions that could be revealed in lung CT scans are nodules, halo signs, 
reverse halo signs, cavities, wedge-shaped infiltrates, pleural effusions – angioinvasion of molds. These need to 
be confirmed by biopsy and molecular or culture based methods. The presence of pulmonary infiltrates in 
neutropenic patients is already a sign of angioinvasion, necrosis, thrombosis, hemorrhage and edema. These can 
be the first observable signs of angioinvasion and systemic fungal infection. CT imaging of infected organs often 
shows limited inflammation around hyphae compared to Aspergillus. The observed lesions can change in the 
course of infection, but are not enough specific to reliably differentiate among causing agents like Aspergillus, 
Scedosporium, Fusarium, Mucorales and mixed infections.The major disadvantage of using CT is exposition of 
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patients on high dose of radiation. The radiation exposure associated with CT scans limits their routinely or serial 
usage. 
Another imaging techniques used in diagnostic is MRI. This method is mandatory for assessing extension into 
cavernous sinus and identifying cerebral involvement. The lesions which can be revealed by MRI are: orbital and 
intradural expansion, cavernous sinus thrombosis, or thrombosis or aneurysm of internal carotid artery. 
The highest sensitivity among imaging methods of diagnostic has positron emission tomography - PET. This 
technique can detect small infectious foci before the onset of the anatomical abnormalities assessed by 
conventional radiology tools. PET is not recommended for the evaluation of cerebral involvement and also in 
diabetic patients control of glycaemia is required. 
Preliminary diagnosis based of above described techniques needs to be confirmed by biopsy and molecular or 
culture based methods. 
Direct examination and culture based methods 
Direct examination can provide only limited information on the causing agent. But in the absence of the quick 
diagnostic test, biopsy with histopathological assessment remains the crucial method in diagnosis of zygomycosis. 
In tissues materials zygomycosis can be recognized by presence of broad, nonseptate hyphae, invading tissue and 
cause necrosis, vascular invasion and thrombosis. The hyphae of Zygomycota are branched at a right angle, 
opposite to other fungi such as Aspergillus which hyphae branch at a slight angles. However they can be easily 
overlooked in tissue samples stained with non-fungal staining. Many infections get a definitive diagnosis only in 
autopsy. 
For diagnosing of mucormycosis different specimens are taken adequate to the location of the ongoing process of 
infection. For rhinocerebral form the appropriate samples are as followed sinus aspirates, tissue specimens from 
affected area and also scraping of the nasal mucosa. In case of pulmonary infection it can be obtained deep samples 
of tissues and bronchoalveolar lavage (BAL) with flexible fiberoptic bronchoscopy. Sputum testing has lower 
sensitivity especially in non-neutropenic patients. CT-guided biopsy can be also performed in case of negative 
BAL findings (Lass-Flörl et al., 2007). 
The biopsy of the lesion is necessary to establish the diagnosis of cutaneous mucormycosis . The biopsy specimen 
should be taken from the center of the lesion and include subcutaneous fat, because molds frequently invade blood 
vessels of the dermis and subcutis, resulting in an ischemic cone at the skin surface.41 Impression smears from 
the wound edges may also help in the diagnosis (A Skiada et al., 2012). 
Culture is useful for identification of etiological agents and antifungal drug susceptibility testing. Mucorales are 
fast growing molds, so a 24 h incubation on fungal media like Sabouraud Agar and Malt Extract Agar at 25-37 °C 
usually suffices for colony formation. A positive culture in a patients with no clinical symptoms should be 
interpreted with caution because of possibility of environmental contamination. Besides classic morphological 
identification of molds there are some metabolic markers important for species/genus identification such as ability 
to grow in certain temperature ranges and assimilation of different compounds as a sole carbon sources.  
Human pathogenic Mucorales differ in carbon sources utilization patterns (Schwarz, Lortholary, Dromer, & 
Dannaoui, 2007), what could be used for species identification either directly in culture dependent assays or for 
the development of metabolite based approaches. There is limited data on species differences in 
pathology/treatment due to very recent establishment of some of the aforementioned new taxa. Differential carbon 
source usage was reported for Apophysomyces with negative results for D-galactose and other sugars (Eduardo 
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Alvarez et al., 2010)assimilation and positive for the members of six other genera of pathogenic Zygomycota, i.e. 
Cunninghamella, Lichtheimia, Mucor, Rhizopus, Rhizomucor and Syncephalastrum (Schwarz et al., 2007). Such 
differences might be used to develop identification tests. 
Species identification can be confirmed by molecular methods based on sequencing of a standard PCR product 
obtained with universal fungal ITS primers on DNA extracted from a culture enables reliable order/species level 
identification of the infecting fungus. A second possibility in laboratories equipped with reference libraries is 
techniques such as MALDI-TOF from culture samples. 
Culture independent methods - Molecular diagnosis 
Currently there are no circulating antigen detection tests available. The promising 1,3 beta-D-glucan tests are 
commonly found to be negative in Mucorales. A double galactomannan and 1,3 beta-D-glucan test can be of help 
in excluding invasive aspergillosis or a double infection by Aspergillus and Mucorales. PCR based tests of blood 
samples are not yet available. In consequence biological samples of the infected sites should be collected for 
histopathology and culture. Invasive diagnostics biopsy of infected tissue in sinus and lung infection should be 
performed. Blood and cerebrospinal fluid are usually culture negative. 
Culture independent molecular techniques are being developed some are complex and laborious (Zhao et al., 2011) 
other require sophisticated equipment and reference datasets. Zhao and colleagues describe an assay based on a 
combination of broad-range PCR amplification and reverse line blot hybridization (PCR/RLB) which enabled 
them to identify fungi from tissue samples in 7h hours (Zhao et al., 2011) with high specificity (no false positives) 
and false negatives solely for fungi not included in the reference. Additionally their methods works for 
concentrations of 1.8 × 10−3 ng/μl of genomic DNA. 
More specific and sensitive molecular markers, secondary metabolite identification methods are still being 
developed. 
MALDI-TOF diagnostics are currently based on reference datasets and require cultivation however a development 
of serum based profiles is expected in the closest future. 
Treatment 
According to the largest meta-analysis performed by Roden and colleagues (Roden et al., 2005) lack of treatment 
had a fatal outcome with only 3% of survival. A double treatment consisting of antifungal therapy combined 
with surgical interventions was the most successful leading to the survival of 70% of patients. 
Early diagnosis is the key factor for a successful outcome  (Roden et al., 2005). This is followed by surgical 
debridement and antifungal therapy. Necrotic tissue resulting from disease progression may require repeated 
excision as it prevents antifungal agent penetration (Anna Skiada et al., 2013). Amphotericin B is the main drug 
used in the treatment of mucoromycosis, entomophtoromycosis and mortierellomycosis. High therapeutic dosage 
should be achieved as soon as possible. Lipid formulations tend to be better tolerated, limiting the nephrotoxicity 
(Antoniadou & Dupont, 2005). Currently, no other drug displays comparable activity against all three groups of 
fungi. The main antifungal drugs belong to five different groups echinocandins, azoles, polyenes, allyamines and 
pyrimidine analogues. The echinocandins (caspofungin, micafungin and anidulafungin) inhibit the synthesis of 
1,3-β-D-glucan, an essential component of the fungal cell wall. Azoles (fluconazole, hexaconazole, isavuconazole, 
itraconazole, posaconazole, ravuconazole, voriconazole) are lanosterol 14 alpha-demethylase inhibitors. Polyenes 
bind ergosterol a cell membrane component (Amphotericin B, nystatin, and natamycin). Allylamines inhibit 
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squalene monooxygenase among them only Terbinafine is used against fungi. The main antifungal pyrimidine 
analogue and thymidylate synthase inhibitor is Flucytosine. 
An evaluation of amphotericin B, ketoconazole, fluconazole, intraconazole, voriconazole, posaconazole, 
caspofungin and flucytosine activity against most of the human pathogenic Mucorales: Rhizopus sp., R. arrhizus, 
R. microsporus var. rhizopodiformis, R. microsporus var. micorsporus, Mucor sp., M. circinelloides group, 
Rhizomucor sp., Absidia sp., Absidia corymbifera, Cunninghamella sp., Apophysomyces elegans revealed that 
posaconazole is the second most promising drug (Lewis et al., 2012). A recent report from the 3rd European 
Conference on Infections in Leukemia (ECIL 3) provides a detailed guideline regarding diagnosis and treatment 
and lists yet unanswered questions (Anna Skiada et al., 2013). 
Amphotericin B 
Amphotericin B deoxycholate was introduced more than 50 years ago and become the gold standard of therapy of 
invasive mycoses (Antoniadou & Dupont, 2005; Klepser, 2011). It has a broad spectrum activity against most 
fungal agents and serves as a reference in searches for novel antifungal drugs. The administration of AMB causes 
severe side effects among them high nephrotoxicity what lead to the development of less nephrotoxic lipid 
formulations. The latter can be administrated in higher doses than the native drug. Comparative trials are performed 
between the more common Liposomal amphotericin B (LAmB) and Amphotericin B colloidal dispersion (ABCD) 
which is less studied.  
Posaconazole 
Posaconazole is an exception among azoles which display either moderate or no activity against most of the tested 
strains . Mucorales are in general susceptible to amphotericin B, but display variable response to posaconazole. A 
recent report from the SEIFEM and FUNGISCOPE (Pagano et al., 2006, 2013) registries evaluated the outcome 
from combined lipid formulation of amphotericin B (LAmpB) posaconazole (POS) therapy of invasive 
mucormycosis in 32 patients (Pagano et al., 2013). This evaluation was essential due to limited number of cases 
in previous clinical reports and inconclusive previous studies which reported synergistic effects in vitro and no 
improvement relative to LAmpB monotherapy in mouse models. Pagano and colleagues conclude that a combined 
therapy should be considered in severe cases of invasive mucormycosis. Additionally, it is recommended to 
consider prophylaxis with posaconazole in risk groups. It is a broad spectrum drug protective against Zygomycota 
and Fusarium, Penicillium, Histoplasma, Blastomyces, Coccidioides, Paracoccidioides, Sporotrix, 
chromoblastomycosis, mycetoma, phaeohyphomycosis, including Scedosporium apiospermum and Exophiala, 
Alternaria, and Bipolaris species (Scheinfeld, 2007). Among others it has been used for successful treatment of 
Cunninghamella elegans infection (Garbino, Myers, Ambrosioni, & Gumy-Pause, 2010). Furthermore it is the 
most active drug in A. elegans treatment, has lower MIC than AmpB (A Chakrabarti et al., 2010). Saksenaeaceae 
(Apophysomyces and Saksenaea) seem to be most responsive to antifungals posaconazole, itraconazole, and 
terbinafine (Hospenthal et al., 2011)and not AmpB. 
Vorionazole  
Previous exposure of Rhizopus oryzae to voriconazole enhances virulence in animal models (Lamaris et al., 2009; 
Lewis, Liao, Wang, Prince, & Kontoyiannis, 2011)) It is discussed whether the co-occurrence of voriconazole 
application in antifungal prophylaxis in immunocompromised patients with the frequency of zygomycosis has a 
causal character (Pongas et al., 2009) 
Caspofungin 
17 
 
Reports on caspofungin treatment show discrepancies between in vitro and in vivo results. Caspofungin is 
claimed to facilitate the development of some zygomycoses similarly to voriconazole and is associated with a 
worse outcome (A Skiada et al., 2011). On the other hand caspofungin shows synergy with AmpB in mice model 
(Spellberg, Fu, Edwards, & Ibrahim, 2005). There is a repeatedly confirmed paradox of caspofungin efficacy 
decreasing to control level, when administrated in higher doses in murine models (Lewis, Leventakos, Liao, & 
Kontoyiannis, 2011). 
 Terbinafine 
Recently,  terbinafine has been successfully applied to patients with mucormycosis (Keller, 2012; Pérez, 1999; 
Revankar, Nailor, & Sobel, 2008). The drug has been primary against dermatophytes but further usage included 
Candida and Zygomycota. Terbinafine was the most active compound (among amphotericin B, voriconazole, 
posaconazole, itraconazole, ravuconazole, terbinafine, and caspofungin) in an in vitro study of antifungal activity 
against five strains of Cunninghamella bertholletiae and four of Cunninghamella echinulata (Pastor et al., 2010). 
However, it is intriguing why in vivo studies did not include this compound. Nevertheless the compound was 
successfully applied against Basidiobolus ranarum in a combination with itraconazole in a rhino-facial infection 
(Goyal, Gupta, Das, & Jain, 2010). 
 
Combined antifungal therapy 
  Spellberg with colleagues (Spellberg, Ibrahim, Chin-Hong, et al., 2012) formulated three recommendations to 
introduce phase III clinical trials with combined therapy: 1) improved survival in relevant animal models of 
mucormycosis 2) available retrospective data that are concordant with the preclinical models both for efficacy and 
safety 3) involvement of already approved therapeutic agents. The consortium proposed three potentially effective 
therapeutic combinations: lipid polyene – echinocandin, lipid polyene/posaconazol – deferasirox, lipid polyene – 
posaconazole/isovuconazole. The aforementioned (L)AmpB and posaconazole combination was the most 
commonly used combined therapy in patients with hematologic diseases reported from the SEIFEM and 
FUNGISCOPE registries. In the aforementioned studies LAmB+POS was administered when antifungal 
monotherapy failed to produce a response. These patients were treated with a monotherapy for a median time of 
18 days before LAmB+POS combined therapy was introduced. A robust and consistent assessment of drug 
efficacy and combined therapy influence on patients outcome is limited by such factors as i) limited number of 
cases ii)  lack of regular therapeutic drug monitoring iii) uncontrolled impact of surgical debridement iv) burden 
of underlying diseases.  
The concluding remark from Pagano and colleagues analyses (Pagano et al., 2013) was, that a combined antifungal 
treatment with LAmB+POS may be considered in patients with very aggressive forms of IM. This is the only drug 
combination which is consistently recommended by independent authorities. However, other combinations have 
been described as well.  
    In vitro studies as well as animal studies suggested a synergistic effect of deferasirox in combination with LAmB 
(Ibrahim et al., 2005). However, a randomized, double-blinded, placebo-controlled trial showed that patients with 
mucormycosis treated with deferasirox with LAmB had a higher mortality rate at 90 days than patients treated 
with LAmB with placebo. Authors underlined that population imbalances in this small Phase II study limit possible 
generalizations. Spellberg and co-authors concluded although no obvious toxicities were identified deferasirox 
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cannot be recommended as part of an initial combination regimen for the treatment of mucormycosis (Spellberg, 
Ibrahim, Roilides, et al., 2012).  
    From the theoretical point of view echinocandins should be active against Mucorales – R. oryzae porduces the 
target enzyme for echinocandins (Ibrahim et al., 2005). In vitro studies shows higher MICs for this group of drugs 
(Vitale et al., 2012). In a mice model of disseminated mucormycosis a combination of caspofungin with ABLC 
(Spellberg, Fu, et al., 2005) and LAmB with either micafungin or anidulafungin (Ibrahim, Gebremariam, Fu, 
Edwards, & Spellberg, 2008) markedly and synergistically improved survival compared to either monotherapy or 
placebo. Reed and colleagues conducted a retrospective study concluding that either ABLC or LAmB combined 
with CASP improved survival for patients with rhinocerebral mucormycosis compared with polyene monotherapy 
(Reed et al., 2008). Micafungin was also successfully combined with LAmpB, however systematic trials are 
missing (Ogawa et al., 2012). This effect was previously observed in an animal model of disseminated 
mucormycosis (Ibrahim et al., 2008). This all data “provide strong rationale for a phase III, randomized double-
blinded, placebo-controlled study to determine whether lipid polyene plus echinocandins are indeed superior to 
lipid polyene plus placebo therapy” - (Spellberg, Ibrahim, Roilides, et al., 2012). 
Alternative therapy 
Iron chelators and hyperbaric oxygen 
Both iron chelators (deferasirox and deferiprone) and hyperbaric oxygen have been used in some cases. 
However, they are not enough well documented to get positive recommendation from ECIL 3(Anna Skiada et 
al., 2013). 
Immunotherapy and immunostimulation 
Adoptive immunotherapy with T cells after stimulation with cellular extracts of fungi may form the basis for future 
clinical trials. A simultaneous stimulation with Aspergillus fumigatus, Candida albicans and Rhizopus oryzae 
extracts enables generation of multi-specific T cells that recognize a wide variety of taxa (Tramsen et al., 2013). 
This in vitro and in vivo results may be a hope for allogeneic hematopoietic stem cell transplantation recipients 
with invasive fungal infection. However, there is no sufficient clinical evidence to formulate recommendations to 
use this approach in systemic zygomycosis (Antachopoulos, Katragkou, & Roilides, 2012). 
The ECIL 3 suggest that growth factors granulocyte colony-stimulating factor (G-CSF), granulocyte- macrophage 
colony-stimulating factor (GM-CSF), and interferon-γ (IFN-γ) should be used in neutropenic patients with 
mucormycosis. Their administration in other patients needs to be further studied. 
Final remarks 
The constantly growing number of patients susceptible to fungal infections emphasizes the critical need for 
better treatment and diagnostics. These can be developed based on rigorous meta-analyses of well described case 
reports with proper taxon identification, treatment and outcome description. 
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